AU · rank #5 · 2026-09-04
FRE
XETRA · EUR · $30.26B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.840 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.05 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 11 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $55.59 | +25.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +19.61% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +25.4% |
| 52w high | $51.53 |
| Market cap (USD) | $30.26B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Fresenius SE & Co. KGaA is a diversified German healthcare company that operates hospital networks and provides medical care services globally [RECENT_DEVELOPMENTS].
Rationale
The quant signal of 100% revision agreement and 25.7% analyst upside is validated by strong underlying momentum, including 12% growth in constant-currency Core EPS driven by its "#FutureFresenius" program [RECENT_DEVELOPMENTS].
Material risks
- 1Operational execution failures or delays in the "Rejuvenate" cost-optimization phase could derail core net income targets and halt the positive earnings revision trajectory [RECENT_DEVELOPMENTS].
- 2Persistently high nursing and clinical staff wage inflation could compress margins across the hospital operations business.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.